Fulcrum Therapeutics Inc (FULC NASDAQ) stock market data APIs
$3.6445
0(0%)
as of October 16, 2026
Try our APIs with
free plan!
Fulcrum Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Prev. Close
3.6445
Open
3.6468
High
3.6548
Low
3.6427
52 wk Range
2.83-15.7399
Market Cap
279 M
Shares Outstanding
76 382 K
EPS
-0.2866
Beta
2.627
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Fulcrum Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Fulcrum Therapeutics Inc data using free add-ons & libraries
Get Fulcrum Therapeutics Inc Fundamental Data
Fulcrum Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -85 396 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Fulcrum Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-04
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fulcrum Therapeutics Inc News
New
Slate Medicines Starts Migraine Treatment Study
By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company's subcutaneous antibody candidate for migraine treatment. P...
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business. Slate is contribut...
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies
By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the...
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
Key Points Interested in Fulcrum Therapeutics, Inc.? Here are five stocks we like better. Fulcrum Therapeutics will merge with migraine biotech Slate Medicines in an all-stock transaction expected to...
Get Fulcrum Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.